Abstract Library

#4163 Metabolite biomarker discovery for pancreatic neuroendocrine tumors using metabolomic approach

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the tumors’ aberrant changes. However, the metabolic plasticity of pancreatic neuroendocrine tumors (pNET) is still unknown. pNETs are heterogeneous which makes their diagnosis, prognosis and therapeutic management difficult.

Conference:

Presenting Author:

Authors: Jannin A, Dessein A, Dabo S, Descat A, Vantyghem M,

Keywords: pancreatic NET, diagnostic biomarker, plasma metabolites, molecular pathways,

#4086 Prognostic significance of metabolomics clusters in extra-pancreatic NETs: Lung NET sub-analysis

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the aberrant changes that support cancer cells proliferation and survival. In a previous metabolomics study carried out by our group, multiplatform untargeted metabolomic profiling (GC-MS, CE-MS and LC-MS) performed on plasma samples from 77 advanced G1-2 extra-pancreatic NET patients demonstrated that these patients have a distinct metabolomic profile, and identified methionine, porphyrin and tryptophan metabolism as the most relevant dysregulated pathways associated with the prognosis of NETs. Furthermore, a 3-metabolite signature was able to stratify patients in 3 distinct prognostic clusters, with cluster 3 associated with the best prognosis.

Conference:

Presenting Author:

Authors: La Salvia A, Lens-Pardo A, Carretero-Puche C, Capdevila J, Benavent M,

Keywords: metabolimics, prognostic biomarker, lung neuroendocrine tumor, metabolomic signature,

#3997 FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression

Introduction: More than 60% of pancreatic neuroendocrine neoplasms (PanNENs) represent metastases when diagnosed. Metabolic alterations have been recognized as one of the hallmarks of tumor metastasis. However, little is known about the molecular mechanism of metabolic changes regulating PanNEN progression.

Conference:

Presenting Author:

Authors: Hu C,

Keywords: metabolic alteration, tumor progression, pancreatic neuroendocrine neoplasm, FOXA2, INHBA, epithelial-mesenchymal transition,

#3807 Key device attributes for Somatostatin Receptor Ligand (SRL) therapy in patients with neuroendocrine tumors (NETs)

Introduction: SRL injection effectiveness, safety and adherence are similar for independent vs healthcare setting administration, but patient preferences and satisfaction with devices vary. For other injectable hormones, device ease of use has been associated with more favourable outcomes. Elucidating preferred SRL device features should help HCPs decide which device best fits individual needs.

Conference:

Presenting Author: Martin W

Authors: Martin W, Kolarova T, Marks M, Follin C, de Herder W,

Keywords: NET, neuroendocrine tumor, somatostatin receptor ligands, SRL, device, preference,

#3725 Progression of pancreatic neuroendocrine tumors (PanNETs) to metastatic disease is associated with MCT4 expression and metabolic heterogeneity

Introduction: Up to 50% of patients with PanNETs present with metastasis at time of diagnosis or relapse after surgery, with highly variable dynamics. The mechanisms driving progression from indolent to metastatic disease are largely unknown. Although having great potential for providing novel therapeutic targets, the metabolic landscape at different tumor stages is only poorly understood. Transcriptome and epigenome analyses of PanNET indicate a potential stepwise progression, which is associated with enhanced proliferation, dedifferentiation and hallmarks of hypoxia.

Conference:

Presenting Author: Sadowski M

Authors: Sadowski M, Bräutigam K, Straub J, Andreasi V, Kirchner P,

Keywords: MCT4, metabolic subtypes, aggressive PanNET, patient-derived tumoroid,